First Surgical National Consensus Conference of the Italian Breast Surgeons association (ANISC) on breast cancer management in neoadjuvant setting: Results and summary

被引:4
作者
De Luca, Alessandro [1 ]
Frusone, Federico [1 ]
Buzzacchino, Federica [2 ]
Amabile, Maria Ida [1 ]
Taffurelli, Mario [3 ]
Del Mastro, Lucia [4 ,5 ]
Rutgers, Emiel J. T. [6 ]
Sacchini, Virgilio [7 ]
Caruso, Francesco [8 ]
Minelli, Mauro [2 ]
Fortunato, Lucio [9 ]
机构
[1] Sapienza Univ Rome, Dept Surg Sci, Vle Regina Margherita 324, I-00161 Rome, Italy
[2] San Giovanni Addolorata Hosp, Div Med Oncol, Rome, Italy
[3] Univ Bologna, IRCCS Policlin SantOrsola, Bologna, Italy
[4] IRCCS Osped Policlin San Martino, Breast Unit, Genoa, Italy
[5] Dept Internal Med & Med Specialties DIMI, Genoa, Italy
[6] Netherlands Canc Inst, Dept Surg, Amsterdam, Netherlands
[7] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10065 USA
[8] Humanitas Catanese Ctr Oncol, Dept Oncol Surg, Catania, Italy
[9] San Giovanni Addolorata Hosp, Breast Ctr, Rome, Italy
来源
EJSO | 2021年 / 47卷 / 08期
关键词
Breast cancer; Neoadjuvant chemotherapy; Consensus; Breast surgery; Axillary surgery; RADIOACTIVE IODINE SEEDS; SENTINEL NODE BIOPSY; CHEMOTHERAPY; THERAPY; MARKING;
D O I
10.1016/j.ejso.2021.04.037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rationale: On October 15th, 2020, the first Surgical National Consensus Conference on neoadjuvant chemotherapy (NACT) was promoted by the Italian Association of Breast Surgeons (ANISC). Method: The Consensus Conference was entirely held online due to anti-Covid-19 restrictions and after an introductory four lectures held by national and international experts in the field, a total of nine questions were presented and a digital "real-time" voting system was obtained. A consensus was reached if 75% or more of all panelists agreed on a given question. Results: A total of 202 physicians, from 76 different Italian Breast Centers homogeneously distributed throughout the Italian country, participated to the Conference. Most participants were surgeons (75%). Consensus was reached for seven out of the nine considered topics, including management of margins and lymph nodes at surgery, and there was good correspondence between the 32 "Expert Panelists" and the "Participants" to the Conference. Consensus was not achieved regarding the indications to NACT for high-grade luminal-like breast tumors, and the need to perform an axillary lymph node dissection in case of micrometastases in the sentinel lymph node after NACT. Conclusions: NACT is a topic of major interest among surgeons, and there is need to develop shared guidelines. While a Consensus was obtained for most issues presented at this Conference, controversies still exist regarding indications to NACT in luminal B-like tumors and management of lymph node micrometastases. There is need for clinical studies and analysis of large databases to improve our knowledge on this subject. (C) 2021 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1913 / 1919
页数:7
相关论文
共 45 条
[1]   Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].
Alberro, J. A. ;
Ballester, B. ;
Deulofeu, P. ;
Fabregas, R. ;
Fraile, M. ;
Gubern, J. M. ;
Janer, J. ;
Moral, A. ;
de Pablo, J. L. ;
Penalva, G. ;
Puig, P. ;
Ramos, M. ;
Rojo, R. ;
Santesteban, P. ;
Serra, C. ;
Sola, M. ;
Solarnau, L. ;
Solsona, J. ;
Veloso, E. ;
Vidal, S. ;
Abe, O. ;
Abe, R. ;
Enomoto, K. ;
Kikuchi, K. ;
Koyama, H. ;
Masuda, H. ;
Nomura, Y. ;
Ohashi, Y. ;
Sakai, K. ;
Sugimachi, K. ;
Toi, M. ;
Tominaga, T. ;
Uchino, J. ;
Yoshida, M. ;
Coles, C. E. ;
Haybittle, J. L. ;
Moebus, V. ;
Leonard, C. F. ;
Calais, G. ;
Garaud, P. ;
Collett, V. ;
Davies, C. ;
Delmestri, A. ;
Sayer, J. ;
Harvey, V. J. ;
Holdaway, I. M. ;
Kay, R. G. ;
Mason, B. H. ;
Forbe, J. F. ;
Franci, P. A. .
LANCET ONCOLOGY, 2018, 19 (01) :27-39
[2]   Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection [J].
Armer, Jane M. ;
Ballman, Karla V. ;
McCall, Linda ;
Ostby, Pamela L. ;
Zagar, Eris ;
Kuerer, Henry M. ;
Hunt, Kelly K. ;
Boughey, Judy C. .
JAMA SURGERY, 2019, 154 (09) :800-809
[3]   Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study [J].
Boileau, Jean-Francois ;
Poirier, Brigitte ;
Basik, Mark ;
Holloway, Claire M. B. ;
Gaboury, Louis ;
Sideris, Lucas ;
Meterissian, Sarkis ;
Arnaout, Angel ;
Brackstone, Muriel ;
McCready, David R. ;
Karp, Stephen E. ;
Trop, Isabelle ;
Lisbona, Andre ;
Wright, Frances C. ;
Younan, Rami J. ;
Provencher, Louise ;
Patocskai, Erica ;
Omeroglu, Atilla ;
Robidoux, Andre .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :258-U150
[4]   Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial [J].
Boughey, Judy C. ;
Suman, Vera J. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Kuerer, Henry M. ;
Bowling, Monet ;
Flippo-Morton, Teresa S. ;
Byrd, David R. ;
Ollila, David W. ;
Julian, Thomas B. ;
McLaughlin, Sarah A. ;
McCall, Linda ;
Symmans, W. Fraser ;
Le-Petross, Huong T. ;
Haffty, Bruce G. ;
Buchholz, Thomas A. ;
Nelson, Heidi ;
Hunt, Kelly K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14) :1455-1461
[5]   Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Cardoso, F. ;
Kyriakides, S. ;
Ohno, S. ;
Penault-Llorca, F. ;
Poortmans, P. ;
Rubio, I. T. ;
Zackrisson, S. ;
Senkus, E. .
ANNALS OF ONCOLOGY, 2019, 30 (08) :1194-1220
[6]   Innovations in image-guided preoperative breast lesion localization [J].
Cheang, Ellen ;
Ha, Richard ;
Thornton, Cynthia M. ;
Mango, Victoria L. .
BRITISH JOURNAL OF RADIOLOGY, 2018, 91 (1085)
[7]   Margins in Breast-Conserving Surgery After Neoadjuvant Therapy [J].
Choi, Jungeun ;
Laws, Alison ;
Hu, Jiani ;
Barry, William ;
Golshan, Mehra ;
King, Tari .
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (12) :3541-3547
[8]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[9]   De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 [J].
Curigliano, G. ;
Burstein, H. J. ;
Winer, E. P. ;
Gnant, M. ;
Dubsky, P. ;
Loibl, S. ;
Colleoni, M. ;
Regan, M. M. ;
Piccart-Gebhart, M. ;
Senn, H. -J. ;
Thurlimann, B. ;
Andre, F. ;
Baselga, J. ;
Bergh, J. ;
Bonnefoi, H. ;
Brucker, S. Y. ;
Cardoso, F. ;
Carey, L. ;
Ciruelos, E. ;
Cuzick, J. ;
Denkert, C. ;
Di Leo, A. ;
Ejlertsen, B. ;
Francis, P. ;
Galimberti, V. ;
Garber, J. ;
Gulluoglu, B. ;
Goodwin, P. ;
Harbeck, N. ;
Hayes, D. F. ;
Huang, C. -S. ;
Huober, J. ;
Khaled, H. ;
Jassem, J. ;
Jiang, Z. ;
Karlsson, P. ;
Morrow, M. ;
Orecchia, R. ;
Osborne, K. C. ;
Pagani, O. ;
Partridge, A. H. ;
Pritchard, K. ;
Ro, J. ;
Rutgers, E. J. T. ;
Sedlmayer, F. ;
Semiglazov, V. ;
Shao, Z. ;
Smith, I. ;
Toi, M. ;
Tutt, A. .
ANNALS OF ONCOLOGY, 2017, 28 (08) :1700-1712
[10]   Neoadjuvant chemotherapy in breast cancer: more than just downsizing [J].
Derks, Marloes G. M. ;
van de Velde, Cornelis J. H. .
LANCET ONCOLOGY, 2018, 19 (01) :2-3